Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic Driving Market Acceleration in the Non-Insulin Therapies For Diabetes Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Non-Insulin Therapies For Diabetes Market Size By 2025?
In recent times, the market size for non-insulin treatments for diabetes has experienced significant growth. Predictions indicate an increase from $19.98 billion in 2024 to $21.41 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period include a rise in diabetes cases, enhanced understanding of diabetes management, increased healthcare spending, lifestyle changes result in higher incidence rates, a boost in diagnoses, increased government efforts toward diabetes care, and a rise in investment in pharmaceutical research and development.

How Big Is the Non-Insulin Therapies For Diabetes Market Size Expected to Grow by 2029?
There is an anticipated strong surge in the non-insulin therapies for diabetes market in the forthcoming years. The market size is projected to expand to $27.9 billion by 2029, with a compound annual growth rate (CAGR) of 6.8%. The expansion during the forecast period is due to factors such as the growing incidence of diabetes, increasing knowledge of diabetes care, the rising use of combination therapies, an increase in the elderly population, the rise in healthcare spending, the broadening scope of telemedicine, and a preference shift towards oral medicines. In the forecasted period, key trends include progress in oral and injectable drugs, advances in drug distribution systems, improvements in oral peptide delivery, the incorporation of telemedicine and digital health solutions, and enhancements in combined therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Which Key Market Drivers Powering Non-Insulin Therapies For Diabetes Market Expansion and Growth?
The escalation in diabetes cases is projected to boost the expansion of the non-insulin therapies for diabetes market. Diabetes, a persistent health issue, is distinguished by elevated levels of glucose (sugar) in the blood and happens when the body fails to produce enough insulin, or exploits it incorrectly. The surge in diabetes cases can be attributed to inactive lifestyle, unhealthy eating habits, genetic susceptibility, growing older population, obesity, racial factors, unawareness, restricted healthcare accessibility, and environmental triggers. Non-insulin treatments for diabetes aid in managing the disease by elevating insulin sensitivity, curtailing glucose creation in the liver, magnifying glucose absorption in muscle cells, and ameliorating overall glycemic control. For example, a report presented by The British Diabetic Association, a UK-based diabetes charity in April 2023, unveiled that 4.3 million people in the UK were diagnosed with diabetes. The registry information of 2021-22 saw an escalation of 148,951 cases compared to those of 2020-21. Moreover, over 2.4 million citizens in the UK are at a heightened risk of developing type 2 diabetes. Consequently, the rise in diabetes prevalence is stimulating the growth of the non-insulin therapies for the diabetes market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Non-Insulin Therapies For Diabetes Market?
In the non-insulin therapies for diabetes market, leading companies are focusing on the creation of personalized diabetes management systems. These are designed to improve patient outcomes through continuous monitoring, data analytics, and individualized treatment strategies. The aim is to tailor treatment and surveillance to each patient's distinct requirements, utilizing live data and analytics to optimize care and outcomes. For example, US-based pharmaceutical company Eli Lilly and Company launched the Tempo personalized diabetes management platform in November 2022. This platform consists of three core components, namely the Tempo Smart Button, the TempoSmart app, and the Tempo Pen, a prefilled insulin pen. These parts work together to offer personalized advice for adults suffering from diabetes. The innovation aims to support adults with type 1 or type 2 diabetes and their healthcare providers in making knowledgeable, data-dependent treatment choices with Lilly insulins.

What Are the Emerging Segments in the Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented -

1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione's, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications

Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp

Who Are the Global Leaders in the Non-Insulin Therapies For Diabetes Market?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

Which are the Top Profitable Regional Markets for the Non-Insulin Therapies For Diabetes Industry?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.